{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T20:25:06Z","timestamp":1787430306057,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"MSD China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12325-026-03619-y","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:37:56Z","timestamp":1782848276000},"page":"4266-4281","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Patterns and Decision Drivers in Chinese Patients with Locally Advanced Cervical Cancer: Results from a National Physician Survey"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8789-6887","authenticated-orcid":false,"given":"Peng","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0860-5862","authenticated-orcid":false,"given":"Yirong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3689-8867","authenticated-orcid":false,"given":"Binqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8264-9152","authenticated-orcid":false,"given":"Shuzhen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4405-8306","authenticated-orcid":false,"given":"Chen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8702-9903","authenticated-orcid":false,"given":"Ming","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9112-1021","authenticated-orcid":false,"given":"Yang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"3","key":"3619_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"3619_CR2","unstructured":"GLOBOCAN: Absolute numbers, Incidence, Females, in 2022, Cervix uteri. https:\/\/gco.iarc.who.int\/today\/en\/dataviz\/pie?mode=population&cancers=23&populations=100_104_108_112_116_12_120_124_132_140_144_148_152_160_170_174_178_180_188_191_192_196_203_204_208_214_218_222_226_231_232_233_24_242_246_250_254_258_262_266_268_270_275_276_288_300_31_312_316_32_320_324_328_332_340_348_352_356_36_360_364_368_372_376_380_384_388_392_398_4_40_400_404_408_410_414_417_418_422_426_428_430_434_44_440_442_450_454_458_462_466_470_474_478_48_480_484_496_498_499_50_504_508_51_512_516_52_524_528_540_548_554_558_56_562_566_578_586_591_598_600_604_608_616_620_624_626_630_634_638_64_642_643_646_662_678_68_682_686_688_694_70_702_703_704_705_706_710_716_72_724_728_729_740_748_752_756_76_760_762_764_768_780_784_788_792_795_8_800_804_807_818_826_834_84_840_854_858_860_862_882_887_894_90_96&group_populations=0&sexes=2&sort_by=value1&types=0&key=total (2022). Accessed 2025\u201306\u201304."},{"issue":"12","key":"3619_CR3","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1136\/ijgc-2022-003801","volume":"32","author":"BJ Monk","year":"2022","unstructured":"Monk BJ, Tan DSP, Hernandez Chagui JD, Takyar J, Paskow MJ, Nunes AT, et al. Proportions and incidence of locally advanced cervical cancer: a global systematic literature review. Int J Gynecol Cancer. 2022;32(12):1531\u20139. https:\/\/doi.org\/10.1136\/ijgc-2022-003801.","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"3619_CR4","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/ijgc-2019-001135","volume":"30","author":"J Mayadev","year":"2020","unstructured":"Mayadev J, Nunes AT, Li M, Marcovitz M, Lanasa MC, Monk BJ. CALLA: efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study. Int J Gynecol Cancer. 2020;30(7):1065\u201370. https:\/\/doi.org\/10.1136\/ijgc-2019-001135.","journal-title":"Int J Gynecol Cancer"},{"key":"3619_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ygyno.2023.10.017","volume":"179","author":"E Girda","year":"2023","unstructured":"Girda E, Randall LM, Chino F, Monk BJ, Farley JH, O\u2019Cearbhaill RE. Cervical cancer treatment update: a Society of Gynecologic Oncology clinical practice statement. Gynecol Oncol. 2023;179:115\u201322. https:\/\/doi.org\/10.1016\/j.ygyno.2023.10.017.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"3619_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1136\/ijgc-2023-004429","volume":"33","author":"D Cibula","year":"2023","unstructured":"Cibula D, Raspollini MR, Planchamp F, Centeno C, Chargari C, Felix A, et al. ESGO\/ESTRO\/ESP guidelines for the management of patients with cervical cancer\u2014update 2023. Int J Gynecol Cancer. 2023;33(5):649\u201366. https:\/\/doi.org\/10.1136\/ijgc-2023-004429.","journal-title":"Int J Gynecol Cancer"},{"key":"3619_CR7","unstructured":"NCCN: NCCN Guidelines Version 2.2026 Cervical Cancer. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cervical.pdf (2026). Accessed 2026\u201303\u201311 2026."},{"key":"3619_CR8","unstructured":"CSCO. CSCO Guidelines for the Diagnosis and Treatment of Cervical Cancer (2024 Edition). 2024."},{"key":"3619_CR9","unstructured":"CSGO. Chinese Clinical Practice Guidelines for Gynecologic Oncology (2024 Edition). 2024."},{"key":"3619_CR10","doi-asserted-by":"publisher","first-page":"745522","DOI":"10.3389\/fonc.2022.745522","volume":"12","author":"Y Qiao","year":"2022","unstructured":"Qiao Y, Li H, Peng B. Neoadjuvant and adjuvant treatments compared to concurrent chemoradiotherapy for patients with locally advanced cervical cancer: a Bayesian network meta-analysis. Front Oncol. 2022;12:745522. https:\/\/doi.org\/10.3389\/fonc.2022.745522.","journal-title":"Front Oncol"},{"issue":"35","key":"3619_CR11","doi-asserted-by":"publisher","first-page":"5802","DOI":"10.1200\/JCO.2008.16.4368","volume":"26","author":"Chemoradiotherapy for Cervical Cancer Meta-Analysis C","year":"2008","unstructured":"Chemoradiotherapy for Cervical Cancer Meta-Analysis C. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26(35):5802\u201312. https:\/\/doi.org\/10.1200\/JCO.2008.16.4368.","journal-title":"J Clin Oncol"},{"issue":"16","key":"3619_CR12","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1200\/JCO.2017.75.9985","volume":"36","author":"S Gupta","year":"2018","unstructured":"Gupta S, Maheshwari A, Parab P, Mahantshetty U, Hawaldar R, Sastri Chopra S, et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. J Clin Oncol. 2018;36(16):1548\u201355. https:\/\/doi.org\/10.1200\/JCO.2017.75.9985.","journal-title":"J Clin Oncol"},{"issue":"32","key":"3619_CR13","doi-asserted-by":"publisher","first-page":"5035","DOI":"10.1200\/JCO.22.02852","volume":"41","author":"GG Kenter","year":"2023","unstructured":"Kenter GG, Greggi S, Vergote I, Katsaros D, Kobierski J, van Doorn H, et al. Randomized phase III study comparing neoadjuvant chemotherapy followed by surgery versus chemoradiation in stage IB2-IIB cervical cancer: EORTC-55994. J Clin Oncol. 2023;41(32):5035\u201343. https:\/\/doi.org\/10.1200\/JCO.22.02852.","journal-title":"J Clin Oncol"},{"key":"3619_CR14","doi-asserted-by":"crossref","unstructured":"Lai C-H, Goh JC, Domingo EJ, Kim JH, Peng P, Grillo V, et al. Treatment patterns and disparities in locally advanced cervical cancer: insights from the Asia Pacific region. Journal of Gynecologic Oncology. The 8th Biennial Meeting of the Asian Society of Gynecologic Oncology, 2023. p. S8.","DOI":"10.3802\/jgo.2024.35.S1.0060"},{"issue":"1","key":"3619_CR15","first-page":"82","volume":"37","author":"L Jiaqi","year":"2021","unstructured":"Jiaqi L, Pengfei L, Mei J, Danbo W, Yi Z, Biliang C, et al. A survey analysis of standardized diagnosis and treatment of cervical cancer based on Chinese clinical big data. Chin J Pract Gynecol Obstetr. 2021;37(1):82\u20136.","journal-title":"Chin J Pract Gynecol Obstetr"},{"issue":"3","key":"3619_CR16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.21147\/j.issn.1000-9604.2022.03.06","volume":"34","author":"China NHCotPsRo","year":"2022","unstructured":"China NHCotPsRo. National guidelines for diagnosis and treatment of cervical cancer 2022 in China (English version). Chin J Cancer Res. 2022;34(3):256\u201369. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2022.03.06.","journal-title":"Chin J Cancer Res"},{"issue":"12","key":"3619_CR17","doi-asserted-by":"publisher","first-page":"e1945","DOI":"10.1016\/S2214-109X(24)00355-3","volume":"12","author":"H Zhu","year":"2024","unstructured":"Zhu H, Chua MLK, Chitapanarux I, Kaidar-Person O, Mwaba C, Alghamdi M, et al. Global radiotherapy demands and corresponding radiotherapy-professional workforce requirements in 2022 and predicted to 2050: a population-based study. Lancet Glob Health. 2024;12(12):e1945\u201353. https:\/\/doi.org\/10.1016\/S2214-109X(24)00355-3.","journal-title":"Lancet Glob Health"},{"issue":"6","key":"3619_CR18","doi-asserted-by":"publisher","first-page":"675","DOI":"10.21147\/j.issn.1000-9604.2023.06.11","volume":"35","author":"H Chen","year":"2023","unstructured":"Chen H, Zhao X, Hu S, You T, Xia C, Gao M, et al. Estimation of economic burden throughout course of cervical squamous intraepithelial lesion and cervical cancer in China: a nationwide multicenter cross-sectional study. Chin J Cancer Res. 2023;35(6):675\u201385. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2023.06.11.","journal-title":"Chin J Cancer Res"},{"issue":"5","key":"3619_CR19","doi-asserted-by":"publisher","first-page":"e0232129","DOI":"10.1371\/journal.pone.0232129","volume":"15","author":"Q Wu","year":"2020","unstructured":"Wu Q, Jia M, Chen H, Zhang S, Liu Y, Prem K, et al. The economic burden of cervical cancer from diagnosis to one year after final discharge in Henan Province, China: a retrospective case series study. PLoS ONE. 2020;15(5):e0232129. https:\/\/doi.org\/10.1371\/journal.pone.0232129.","journal-title":"PLoS ONE"},{"issue":"3","key":"3619_CR20","doi-asserted-by":"publisher","first-page":"286 e1","DOI":"10.1016\/j.ajog.2020.08.039","volume":"224","author":"M Blanco","year":"2021","unstructured":"Blanco M, Chen L, Melamed A, Tergas AI, Khoury-Collado F, Hou JY, et al. Cost of care for the initial management of cervical cancer in women with commercial insurance. Am J Obstet Gynecol. 2021;224(3):286 e1-e11. https:\/\/doi.org\/10.1016\/j.ajog.2020.08.039.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"3619_CR21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12957-022-02859-w","volume":"20","author":"Y Sun","year":"2022","unstructured":"Sun Y, Li G, Hai P, Cao Y, Han P, Liu Y, et al. The comparative study for survival outcome of locally advanced cervical cancer treated by neoadjuvant arterial interventional chemotherapy or intravenous chemotherapy followed by surgery or concurrent chemoradiation. World J Surg Oncol. 2022;20(1):389. https:\/\/doi.org\/10.1186\/s12957-022-02859-w.","journal-title":"World J Surg Oncol"},{"issue":"3","key":"3619_CR22","first-page":"258","volume":"21","author":"Z Anna","year":"2020","unstructured":"Anna Z, Mingfei G, Yinping M, Yan L, LI Z, Congzhu L, et al. Comparison of different treatment patterns of locally advanced cervical carcinoma. Chin J Clin Obstet Gynecol. 2020;21(3):258.","journal-title":"Chin J Clin Obstet Gynecol"},{"issue":"1","key":"3619_CR23","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1186\/s12885-025-14196-8","volume":"25","author":"HY Yoon","year":"2025","unstructured":"Yoon HY, Kim JM, Jeong YY, Lee YH, Kim MJ, Choi YS, et al. Comparison of oncological outcomes and complication rate between radical hysterectomy and concurrent chemoradiotherapy in stage IIICr cervical cancer without parametrial invasion. BMC Cancer. 2025;25(1):811. https:\/\/doi.org\/10.1186\/s12885-025-14196-8.","journal-title":"BMC Cancer"},{"issue":"8","key":"3619_CR24","doi-asserted-by":"publisher","first-page":"CD010260","DOI":"10.1002\/14651858.CD010260.pub3","volume":"8","author":"F Kokka","year":"2022","unstructured":"Kokka F, Bryant A, Olaitan A, Brockbank E, Powell M, Oram D. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer. Cochrane Database Syst Rev. 2022;8(8):CD010260. https:\/\/doi.org\/10.1002\/14651858.CD010260.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"3619_CR25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.552","author":"RL Nohmi","year":"2025","unstructured":"Nohmi RL, Mamede I, Riya IJ, Gazzoni G, Piya IJ, Martani D, et al. Adjuvant, neoadjuvant and surgical treatment for locally advanced cervical cancer: a network meta-analysis. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.552.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3619_CR26","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.3802\/jgo.2024.35.e15","volume":"35","author":"M Seino","year":"2024","unstructured":"Seino M, Nagase S, Tokunaga H, Yamagami W, Kobayashi Y, Tabata T, et al. Japan Society of Gynecologic Oncology 2022 guidelines for uterine cervical neoplasm treatment. J Gynecol Oncol. 2024;35(1):e15. https:\/\/doi.org\/10.3802\/jgo.2024.35.e15.","journal-title":"J Gynecol Oncol"},{"issue":"Suppl 1(Suppl 1","key":"3619_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/ijgo.13865","volume":"155","author":"N Bhatla","year":"2021","unstructured":"Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet. 2021;155(Suppl 1(Suppl 1)):28\u201344. https:\/\/doi.org\/10.1002\/ijgo.13865.","journal-title":"Int J Gynaecol Obstet"},{"issue":"11","key":"3619_CR28","doi-asserted-by":"publisher","first-page":"108522","DOI":"10.1016\/j.ejso.2024.108522","volume":"50","author":"W Guo","year":"2024","unstructured":"Guo W, Ren R, Li N, Hu Y. Prognosis and treatment regimens for patients with different lymph node statuses in locally advanced cervical cancer. Eur J Surg Oncol. 2024;50(11):108522. https:\/\/doi.org\/10.1016\/j.ejso.2024.108522.","journal-title":"Eur J Surg Oncol"},{"issue":"9","key":"3619_CR29","doi-asserted-by":"publisher","first-page":"CD012246","DOI":"10.1002\/14651858.CD012246.pub2","volume":"9","author":"M Chakrabarti","year":"2022","unstructured":"Chakrabarti M, Nordin A, Khodabocus J. Debulking hysterectomy followed by chemoradiotherapy versus chemoradiotherapy for FIGO stage (2019) IB3\/II cervical cancer. Cochrane Database Syst Rev. 2022;9(9):CD012246. https:\/\/doi.org\/10.1002\/14651858.CD012246.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"3619_CR30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3760\/cma.j.cn112141-20241218-00682","volume":"60","author":"Gynecologic Oncology Subgroup COaGA, Chinese Medical Doctor Association","year":"2025","unstructured":"Gynecologic Oncology Subgroup COaGA, Chinese Medical Doctor Association, Gynecologic Oncology Subgroup MISC, Chinese Medical Doctor Association. Multi-disciplinary treatment approach in cervical cancer care: Chinese gynecologic oncologists consensus. Zhonghua Fu Chan Ke Za Zhi. 2025;60(4):241\u201359. https:\/\/doi.org\/10.3760\/cma.j.cn112141-20241218-00682.","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"3619_CR31","doi-asserted-by":"publisher","first-page":"1160626","DOI":"10.3389\/fonc.2023.1160626","volume":"13","author":"J Huang","year":"2023","unstructured":"Huang J, Zeng X, Chen H, Luo D, Li R, Wu X, et al. Clinical analysis of decision implementation by a multidisciplinary team in cervical cancer cases in Ganzhou, China. Front Oncol. 2023;13:1160626. https:\/\/doi.org\/10.3389\/fonc.2023.1160626.","journal-title":"Front Oncol"},{"issue":"9","key":"3619_CR32","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1002\/cam4.4432","volume":"11","author":"TH Tran","year":"2022","unstructured":"Tran TH, de Boer J, Gyorki DE, Krishnasamy M. Optimising the quality of multidisciplinary team meetings: a narrative review. Cancer Med. 2022;11(9):1965\u201371. https:\/\/doi.org\/10.1002\/cam4.4432.","journal-title":"Cancer Med"},{"issue":"5","key":"3619_CR33","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.3802\/jgo.2023.34.e64","volume":"34","author":"J Qiu","year":"2023","unstructured":"Qiu J, Sun S, Liu Q, Fu J, Huang Y, Hua K. A comparison of concurrent chemoradiotherapy and radical surgery in patients with specific locally advanced cervical cancer (stage IB3, IIA2, IIICr): trial protocol for a randomized controlled study (C-CRAL trial). J Gynecol Oncol. 2023;34(5):e64. https:\/\/doi.org\/10.3802\/jgo.2023.34.e64.","journal-title":"J Gynecol Oncol"},{"key":"3619_CR34","doi-asserted-by":"publisher","first-page":"1034907","DOI":"10.3389\/fpubh.2022.1034907","volume":"10","author":"Y Li","year":"2022","unstructured":"Li Y, Lv X, Liang J, Dong H, Chen C. The development and progress of health literacy in China. Front Public Health. 2022;10:1034907. https:\/\/doi.org\/10.3389\/fpubh.2022.1034907.","journal-title":"Front Public Health"},{"issue":"1","key":"3619_CR35","doi-asserted-by":"publisher","first-page":"82","DOI":"10.19538\/j.fk2021010120","volume":"37","author":"L Jiaqi","year":"2021","unstructured":"Jiaqi L, Pengfei L, Mei J, Danbo W, Yi Z, Biliang C, et al. Investigation and analysis of standardization of diagnosis and treatment of cervical cancer based on big data of clinical diagnosis and treatment of cervical cancer in China. Chin J Pract Gynecol Obstetr. 2021;37(1):82\u20136. https:\/\/doi.org\/10.19538\/j.fk2021010120.","journal-title":"Chin J Pract Gynecol Obstetr"},{"issue":"4","key":"3619_CR36","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.ijrobp.2021.06.019","volume":"111","author":"H Kim","year":"2021","unstructured":"Kim H, Lee YC, Benedict SH, Dyer B, Price M, Rong Y, et al. Dose summation strategies for external beam radiation therapy and brachytherapy in gynecologic malignancy: a review from the NRG Oncology and NCTN Medical Physics Subcommittees. Int J Radiat Oncol Biol Phys. 2021;111(4):999\u20131010. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.06.019.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"3619_CR37","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S1470-2045(20)30753-1","volume":"22","author":"R Potter","year":"2021","unstructured":"Potter R, Tanderup K, Schmid MP, Jurgenliemk-Schulz I, Haie-Meder C, Fokdal LU, et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol. 2021;22(4):538\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(20)30753-1.","journal-title":"Lancet Oncol"},{"issue":"6","key":"3619_CR38","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1136\/ijgc-2022-004180","volume":"33","author":"C Chargari","year":"2023","unstructured":"Chargari C, Tanderup K, Planchamp F, Chiva L, Humphrey P, Sturdza A, et al. ESGO\/ESTRO quality indicators for radiation therapy of cervical cancer. Int J Gynecol Cancer. 2023;33(6):862\u201375. https:\/\/doi.org\/10.1136\/ijgc-2022-004180.","journal-title":"Int J Gynecol Cancer"},{"key":"3619_CR39","doi-asserted-by":"publisher","first-page":"102004","DOI":"10.1016\/j.gore.2025.102004","volume":"63","author":"M Gross","year":"2026","unstructured":"Gross M, Wang JY, Goff BA, Ma TM, Kang KH, Doll KM, et al. Treatment delay and prolongation in locally advanced cervical cancer. Gynecol Oncol Rep. 2026;63:102004. https:\/\/doi.org\/10.1016\/j.gore.2025.102004.","journal-title":"Gynecol Oncol Rep"},{"issue":"2","key":"3619_CR40","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/cncr.27652","volume":"119","author":"S Song","year":"2013","unstructured":"Song S, Rudra S, Hasselle MD, Dorn PL, Mell LK, Mundt AJ, et al. The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy. Cancer. 2013;119(2):325\u201331. https:\/\/doi.org\/10.1002\/cncr.27652.","journal-title":"Cancer"},{"issue":"5","key":"3619_CR41","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/0360-3016(94)00635-X","volume":"32","author":"DG Petereit","year":"1995","unstructured":"Petereit DG, Sarkaria JN, Chappell R, Fowler JF, Hartmann TJ, Kinsella TJ, et al. The adverse effect of treatment prolongation in cervical carcinoma. Int J Radiat Oncol Biol Phys. 1995;32(5):1301\u20137. https:\/\/doi.org\/10.1016\/0360-3016(94)00635-X.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"3619_CR42","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/0360-3016(95)00220-S","volume":"32","author":"CA Perez","year":"1995","unstructured":"Perez CA, Grigsby PW, Castro-Vita H, Lockett MA. Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 1995;32(5):1275\u201388. https:\/\/doi.org\/10.1016\/0360-3016(95)00220-S.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10460","key":"3619_CR43","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S0140-6736(24)01808-7","volume":"404","author":"D Lorusso","year":"2024","unstructured":"Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;404(10460):1321\u201332. https:\/\/doi.org\/10.1016\/S0140-6736(24)01808-7.","journal-title":"Lancet"},{"issue":"10434","key":"3619_CR44","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","volume":"403","author":"D Lorusso","year":"2024","unstructured":"Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet. 2024;403(10434):1341\u201350.","journal-title":"Lancet"},{"issue":"17_suppl","key":"3619_CR45","doi-asserted-by":"publisher","first-page":"LBA5504","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA5504","volume":"43","author":"LR Duska","year":"2025","unstructured":"Duska LR, Xiang Y, Hasegawa K, Ramos-Elias PA, Barreto PRV, Acevedo A, et al. Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: final analysis results of the phase 3, randomized, double-blind ENGOT-cx11\/GOG-3047\/KEYNOTE-A18 study. J Clin Oncol. 2025;43(17_suppl):LBA5504. https:\/\/doi.org\/10.1200\/JCO.2025.43.17_suppl.LBA5504.","journal-title":"J Clin Oncol"},{"key":"3619_CR46","unstructured":"(NMPA) NMPA: NMPA Keytruda Prescribing information. https:\/\/www.msdchina.com.cn\/index?s3_key=https:\/\/res.msdchina.com.cn\/sites\/4\/2025\/11\/%E5%8F%AF%E7%91%9E%E8%BE%BE%E8%AF%B4%E6%98%8E%E4%B9%A6-%E8%BF%9B%E5%8F%A3semi-%E7%AE%80%E7%89%88%EF%BC%88%E6%96%B9%E6%AD%A3%E9%BB%914P%EF%BC%89-25.6.25-%E6%9B%B2%E7%BA%BF.pdf (2025). Accessed 2025\u201312\u201309 2025."},{"issue":"6","key":"3619_CR47","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1080\/14737140.2021.1879646","volume":"21","author":"C Gennigens","year":"2021","unstructured":"Gennigens C, De Cuypere M, Hermesse J, Kridelka F, Jerusalem G. Optimal treatment in locally advanced cervical cancer. Expert Rev Anticancer Ther. 2021;21(6):657\u201371. https:\/\/doi.org\/10.1080\/14737140.2021.1879646.","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03619-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03619-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03619-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T20:01:47Z","timestamp":1787428907000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03619-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3619"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03619-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yirong Yin, Binqi Zhang and Shuzhen Yao are employees of MSD China. Peng Peng reports honoraria from Zai Lab, MSD, and Qilu Pharmaceutical Co. Ltd. Yang Xiang is the president-elect of the Chinese Society of Gynecologic Oncology (CSGO). Chen Li and Ming Du have no conflicts of interest to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Boards\/Ethics Committee of Peking Union Medical College Hospital, 2-Aug-2023 (ethics approval number I-25PJ1067). Respondents gave written informed consent prior to inclusion in the study. Publication-related items were included in the informed consent form signed by the participants.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}